Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer

Exclusion Criteria

• •Cancer in situ (CIS) confirmed by biopsy pathology.
• •Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4(CTLA)-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways (excluding BCG treatment).
• •Received other approved systemic anticancer therapy or systemic immunomodulators within 28 days prior to enrollment.
• •Severe chronic or active infection requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to enrollment
• •Received herbal or proprietary Chinese medicine for cancer inhibition within 14 days prior to admission.
• •Received live vaccination within 28 days prior to admission.
• •Has need for long-term heavy use of hormones or other immunosuppressive drugs.
• •Potassium, sodium, or calcium abnormalities affecting treatment, interstitial lung disease, non-infectious pneumonia, or other uncontrolled systemic diseases, including diabetes, hypertension, or active heart disease.
• •Patients with chronic hepatitis B, hepatitis B virus carriers, or active hepatitis C.
• •Active, known or suspected autoimmune disease requiring systemic therapy.
• •Patients with end-stage renal disease (GFR \<15 mL/min) or requiring dialysis.
• •Other active neoplastic disease.
• •Uncontrolled severe physical or mental illness.
• •Pregnant or lactating women.